KR102066108B1 - Cosmetic compositions containing two kinds of compounds comprising phenyl rings - Google Patents
Cosmetic compositions containing two kinds of compounds comprising phenyl rings Download PDFInfo
- Publication number
- KR102066108B1 KR102066108B1 KR1020130148024A KR20130148024A KR102066108B1 KR 102066108 B1 KR102066108 B1 KR 102066108B1 KR 1020130148024 A KR1020130148024 A KR 1020130148024A KR 20130148024 A KR20130148024 A KR 20130148024A KR 102066108 B1 KR102066108 B1 KR 102066108B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- compounds
- cosmetic composition
- hydroxy
- enyloxy
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Abstract
본 발명은 페닐링을 가지는 2종 화합물을 특정 비율로 포함하는 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition comprising two compounds having a phenyl ring in a specific ratio.
Description
본 발명은 페닐링을 가지는 2종 화합물을 특정 비율로 포함하는 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition comprising two compounds having a phenyl ring in a specific ratio.
일반적으로 결정성 물질을 이용해 기능성 화장료 제형을 제조하기 위해서는 고분자로 이루어진 마이크로캡슐이나 HLB가 높은 계면활성제 등을 이용해 약물의 결정성을 저해하여 피부에 흡수되기 좋은 형태로 용해시켜서 이용하는 것이 보통이다. 그러나, 고분자를 이용하는 마이크로 캡슐은 고분자와의 상용성과 고분자 벽제자체의 결정도에 따라 캡슐내부에서의 약물의 용해도가 결정되며, 대부분의 경우 고분자 캡슐 내에 독립적으로 결정이 형성되어, 약물 방출속도가 매우 느리기 때문에 생체 이용률이 크게 떨어진다는 단점이 있다. 한편, 계면활성제는 결정성 물질의 효율적인 용해를 위해 일정농도 이상의 계면활성제를 사용해야 하는데 이에 따라, 피부 자극을 유발할 수 있다는 단점이 있다. 또한, 계면 활성제는 동적 평형상태로 결정 생성을 저해하므로 주위 환경에 따라 급속도로 결정성장이 이루어져 약물의 생체이용률을 낮춘다는 단점도 있다. In general, in order to prepare a functional cosmetic formulation using a crystalline material, it is common to use a microcapsules made of a polymer or a high HLB surfactant to inhibit the crystallinity of the drug and dissolve it in a form that is easily absorbed by the skin. However, the microcapsules using polymers determine the solubility of the drug in the capsule depending on the compatibility with the polymer and the crystallinity of the polymer wall itself. Because of this, the bioavailability is greatly reduced. On the other hand, the surfactant has to use a certain concentration or more of the surfactant in order to efficiently dissolve the crystalline material, there is a disadvantage that can cause skin irritation. In addition, since the surfactant inhibits crystal formation in a dynamic equilibrium state, crystal growth occurs rapidly according to the surrounding environment, thereby lowering the bioavailability of the drug.
이에 따라, 결정성이 강한 두 개 이상의 물질 간의 용융 시간을 줄이고 용해도를 높여서 피부 흡수율을 높이기 위한 방법에 대해 당업계의 요구가 있었다. Accordingly, there is a need in the art for a method for increasing skin absorption by reducing melting time and increasing solubility between two or more materials having high crystallinity.
본 발명의 목적은 결정성이 강한 두 개 이상의 물질을 녹여서 피부 흡수율을 높게 하는 데 있다. An object of the present invention is to improve the skin absorption rate by dissolving two or more substances having strong crystallinity.
상기 목적을 달성하기 위해 본 발명은 페닐링을 가지는 2 종의 화합물들과 극성 오일을 포함하는, 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition comprising a polar oil and two compounds having a phenyl ring.
본 발명은 또한 페닐링을 가지는 2 종의 화합물들과 극성 오일을 혼합하는 것을 포함하는, 화장료 조성물의 피부 흡수율을 증진시키는 방법을 제공한다. The present invention also provides a method for enhancing the skin absorption rate of a cosmetic composition comprising mixing a polar oil with two compounds having a phenyl ring.
본원발명의 화장료 조성물에 의하면 결정성이 강한 물질간 용융점,즉,녹는 점을 낮추어 주고, 이에 따라 녹는 시간 역시 줄어들며, 결국 용해도를 높이고 피부 흡수율이 증진될 수 있어서, 유용하다. 뿐만 아니라, 이러한 효과는 인체에 유해한 계면활성제를 사용할 필요 없이 가능한 것이므로, 피부 자극 역시 매우 적다. According to the cosmetic composition of the present invention, it is useful because it lowers the melting point, that is, the melting point between materials with strong crystallinity, and thus, the melting time is also reduced, and thus the solubility and the skin absorption rate can be improved. In addition, this effect is possible without the use of surfactants harmful to the human body, so the skin irritation is also very small.
도 1은 본원발명 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 를 각각의 비율로 혼합한 후, 용융점을 살펴본 것이다.
도 2는 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 을 특정 비율로 혼합한 후, 각각의 경우에 비해 용해 속도가 빨라짐을 확인한 것이다.
도 3은 본 발명의 조성물과 대조군에 대해 TEM 이미지로 촬영한 것이다.
도 4는 본 발명의 조성물과 대조군 간에 보이는 피부 흡수율을 관찰한 것이다. 1 is 5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- ( methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3- Dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3 , 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)), and the melting point I will look at.
2 is 5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolane -5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4] -d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) in a specific ratio, and in each case Compared to the faster dissolution rate.
Figure 3 is taken with a TEM image of the composition and the control of the present invention.
Figure 4 observes the skin absorption rate seen between the composition of the present invention and the control.
본원발명은 일 관점에서, 페닐링(Phenyl ring) 기를 가지는 2 종의 화합물들과 극성 오일을 포함하는, 화장료 조성물에 관한 것이다. The present invention, in one aspect, relates to a cosmetic composition comprising a polar oil and two compounds having a phenyl ring group.
본 명세서에서 상기 “페닐링”은 히드록시 기를 포함하는 방향족(aromatic) 고리기를 의미하는 것으로, 이렇게 페닐링이 존재하는 화합물 간에는 파이-파이 반응이 가능하여 공융 혼합물 (eutectic mixture)을 제조할 수 있다. 구체적으로 상기 페닐링 기를 가지는 화합물은 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 을 포함할 수 있으나, 이에 제한되는 것은 아니다. As used herein, the term "phenyl ring" refers to an aromatic ring group including a hydroxy group. Thus, a phenyl ring may be used to prepare a eutectic mixture by allowing a pi-pi reaction between compounds having a phenyl ring. . Specifically, the compound having a phenyl ring group is 5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate (5-methyl 2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1,3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H -benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)), It is not limited to this.
구체적으로 본 발명은 높은 융점(즉, 녹는점)을 갖는 두 가지 약물을 특정한 비율로 혼합시킬 때 생성되는 공융 현상(eutectic)을 이용해, 결정성 활성 물질의 융해점을 낮추어 보다 쉽게 에멀젼을 제조하고, 이를 통해 피부 전달률이 높은 화장료 조성물을 제조할 수 있다. Specifically, the present invention utilizes eutectic produced when two drugs having a high melting point (ie, melting point) are mixed at a specific ratio, thereby lowering the melting point of the crystalline active material to prepare an emulsion more easily. Through this, a cosmetic composition having a high skin delivery rate can be prepared.
상기 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 화합물은 일반적으로 멜라솔브(melasolv)라는 상표명으로 불리기도 하며, 아래 화학식 1과 같은 구조를 가진다. 아울러, 상기 5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl ( 2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) compound is generally referred to as a melasolv brand name, and has a structure as shown in Chemical Formula 1 below. In addition, the above
2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 화합물은 세레티노이드 G(seletinoid G)라는 상표명으로 불리기도 하며, 아래 화학식 2과 같은 구조를 가진다.2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy- 4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy ) -5-hydroxy-4H-pyran-4-one)) compound is also referred to as the brand name serenoidoid G (seletinoid G), and has the structure shown in formula (2) below.
상기 R은 H, ME, Et, Pr 또는 Bu이고, 상기 X는 CO 또는 CH2=CH2CO이다. R is H, ME, Et, Pr or Bu, and X is CO or CH 2 = CH 2 CO.
본 명세서에서 상기 “극성 오일”은 극성을 가지는 오일을 의미할 수 있다. 구체적으로, 에스터 오일 및 페닐계 오일을 포함할 수 있으나, 이에 제한되는 것은 아니다. In the present specification, the "polar oil" may mean an oil having polarity. Specifically, it may include an ester oil and a phenyl-based oil, but is not limited thereto.
본 발명의 일 관점인 화장료 조성물에 있어서, 상기 페닐링을 가지는 2 종의 화합물들은 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 를 포함할 수 있다. In the cosmetic composition of one aspect of the present invention, the two compounds having the phenyl ring are 5-methyl-2- (methylethyl) phenyl (2E) -3- (3, 4, 5-trimethoxyphenyl) Prop-2-enoate (5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 ( 2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) ( 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran -4-one)).
본 발명의 일 관점인 화장료 조성물에 있어서, 상기 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 및 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 화합물 간 중량비는 1:1-4일 수 있다. 상기 중량비 범위 내에서 상기 2종 화합물의 녹는 점이 낮아지고, 이에 따라 시간이 감소하며, 피부 흡수율이 증진될 수 있어서 유용하다. 상기와 같은 관점에서, 상기 2종 화합물 간 중량비는 1:1.1-3.9, 1:1.2-3.8, 1:1.3-3.7, 1:1.4-3.6 또는 1:1.5-3.5일 수 있다. In the cosmetic composition which is an aspect of the present invention, the 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-butyrate 3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5- yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) and 5-methyl-2- (methylethyl) phenyl (2E) -3- (3, 4, 5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) Compound to Weight Ratio May be 1: 1-4. It is useful because the melting point of the two compounds within the weight ratio range is lowered, thereby reducing the time and the skin absorption rate can be enhanced. In view of the above, the weight ratio between the two compounds may be 1: 1.1-3.9, 1: 1.2-3.8, 1: 1.3-3.7, 1: 1.4-3.6 or 1: 1.5-3.5.
본 발명의 일 관점인 화장료 조성물에 있어서, 상기 화장료 조성물은 에멀젼을 포함한다. In the cosmetic composition which is an aspect of the present invention, the cosmetic composition comprises an emulsion.
본 발명은 다른 관점에서, 페닐링을 가지는 2 종의 화합물들과 극성 오일을 혼합하는 것을 포함하는, 화장료 조성물의 피부 흡수율을 증진시키는 방법에 관한 것이다.In another aspect, the present invention relates to a method for enhancing the skin absorption rate of a cosmetic composition, which comprises mixing a polar oil with two compounds having a phenyl ring.
본 발명의 다른 관점인 화장료 조성물의 피부 흡수율을 증진시키는 방법에 있어서, 상기 페닐링을 가지는 2 종의 화합물들은 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one))일 수 있다. In another method of enhancing the skin absorption rate of the cosmetic composition of the present invention, the two compounds having the phenyl ring are 5-methyl-2- (methylethyl) phenyl (2E) -3- (3, 4, 5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2- ((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H- Pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy)- 5-hydroxy-4H-pyran-4-one)).
본 발명의 다른 관점인 화장료 조성물의 피부 흡수율을 증진시키는 방법에 있어서, 상기 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 및 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 화합물 간 중량비는 1:1-4일 수 있다. 상기 중량비 범위 내에서 상기 2종 화합물의 녹는 점이 낮아지고, 이에 따라 시간이 감소하며, 피부 흡수율이 증진될 수 있어서 유용하다. 상기와 같은 관점에서, 상기 2종 화합물 간 중량비는 1:1.1-3.9, 1:1.2-3.8, 1:1.3-3.7, 1:1.4-3.6 또는 1:1.5-3.5일 수 있다.In a method of improving skin absorption of a cosmetic composition which is another aspect of the present invention, the 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl ) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1) , 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) and 5-methyl-2- (methylethyl) phenyl (2E)- 3- (3, 4, 5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop- 2-enoate) the weight ratio between the compounds may be 1: 1-4. It is useful because the melting point of the two compounds within the weight ratio range is lowered, thereby reducing the time and the skin absorption rate can be enhanced. In view of the above, the weight ratio between the two compounds may be 1: 1.1-3.9, 1: 1.2-3.8, 1: 1.3-3.7, 1: 1.4-3.6 or 1: 1.5-3.5.
본 발명의 다른 관점인 화장료 조성물의 피부 흡수율을 증진시키는 방법에 있어서, 상기 화장료 조성물은 에멀젼인, 화장료 조성물의 피부 흡수율을 증진시키는 방법을 포함한다.
In a method of enhancing the skin absorption rate of a cosmetic composition which is another aspect of the present invention, the cosmetic composition includes a method of enhancing the skin absorption rate of the cosmetic composition, which is an emulsion.
이하, 하기의 실시예를 통하여 본 발명을 보다 구체적으로 설명한다. 그러나 하기의 실시예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐, 본 발명의 범주 및 범위가 이에 한정되지 않는다.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are provided only for the purpose of illustration in order to facilitate understanding of the present invention, the scope and scope of the present invention is not limited thereto.
[실시예 1] 용융점 확인 Example 1 Melting Point Verification
멜라솔브와 셀레티노이드의 공융 혼합물 특성을 확인하기 위해 phase diagram을 작성하였다[도1]. 멜라솔브 10g과 셀레티노이드G 10g을 각각 무게 달아, 멜라솔브와 셀레티노이드 G 2성분계에서, 멜라솔브의 초기 농도를 100%에서 0%까지 조절한 시료의 용융점을 DSC()를 통해 측정하여 상태도를 작성하였다. 그 결과, 멜라솔브(melasolv)와 세레티노이드 G(seletinoid G)만 존재하는 경우, 각각의 용융점은 각각 110도와 170도 부근이었다. 반면, 구체적으로, 각각의 화합물을 1:2의 중량비로 혼합한 후에는 70도로 용융점이 저하되는 것을 확인할 수 있었다.
A phase diagram was created to confirm the eutectic mixture properties of melalasolve and selenoids [FIG. 1]. Weigh 10 g of Melasolve and 10 g of Seletinoid G, respectively, and measure the melting point of the sample in which the initial concentration of Melasolve is adjusted from 100% to 0% using DSC (). Created. As a result, when only melasolv and serenoidoid G were present, each melting point was about 110 and 170 degrees, respectively. On the other hand, specifically, after mixing each compound in a weight ratio of 1: 2, it was confirmed that the melting point is lowered to 70 degrees.
[실시예 2] 용해속도 측정 Example 2 Measurement of Dissolution Rate
공융 혼합물의 화장료 도입을 위해 극성 오일을 추가한 뒤 용해되는 정도를 비교하였다. 즉, 세틸에틸헥사노에이트, 리퀴드 파라핀 5:5 혼합물 100g에 공융혼합물 20g 과 멜라솔브 10g, 셀레티노이드G 10g을 각각 녹여 60도로 가온하였다. 이후, 시간별로 쇠 거름망을 이용해 용해되지 않고 부유되어 있는 활성성분을 걸러내고, 알코올로 오일을 제거한 이후에, 질량을 측정하여, 초기 함량 대비 녹는 정도를 확인하였다[도2]. 그 결과, 공융혼합물은 약 10분 뒤에 80% 이상의 용해도를 보인 반면, 단일물의 경우 30% 이하의 용해도를 확인할 수 있었다. 결과적으로 공융혼합물은 단일물에 비해 용해속도와 용해도를 유의한 수준으로 높일 수 있음을 확인하였다.
The degree of dissolution was compared after the addition of the polar oil for cosmetic introduction of the eutectic mixture. That is, 20 g of a eutectic mixture, 10 g of melasolve, and 10 g of selenoid G were dissolved in 100 g of a mixture of cetylethylhexanoate and liquid paraffin 5: 5, and warmed to 60 degrees. Thereafter, by using a strainer to filter the active ingredient suspended without dissolving, and after removing the oil with alcohol, the mass was measured to determine the degree of melting relative to the initial content [Fig. 2]. As a result, the eutectic mixture showed a solubility of 80% or more after about 10 minutes, while the solubility of less than 30% in the case of a single product. As a result, it was confirmed that the eutectic mixture can significantly increase the dissolution rate and solubility compared to the single substance.
[실시예 3] Example 3
실시예 2에서 용해된 공융혼합물/오일, 멜라솔브/오일, 셀레티노이드G/오일 혼합물을 이용해 다음과 같은 조성으로 유화액을 제조하였다.Emulsion was prepared in the following composition using the dissolved eutectic mixture / oil, melasolve / oil, selenoid G / oil mixture in Example 2.
(Squalane)Squalane
(Squalane)
(Carbomer)Carbomer
(Carbomer)
(Triethanolamine)Triethanolamine
(Triethanolamine)
이후에 제조된 고압유화기를 통해 1,000bar/3cycle 로 처리하여 나노 에멀젼을 제조하였다. 제조된 나노 에멀젼에서 활성성분인 멜라솔브와 셀레티오이드 G의 재석출 현상을 확인하기 위하여 투과 전자현미경(TEM)을 이용해 결정현상을 확인하였다.Subsequently, the nanoemulsion was prepared by treating with 1,000bar / 3cycle through a manufactured high pressure emulsifier. In order to confirm the re-precipitation phenomenon of the active ingredient Melasolve and selenide G in the prepared nanoemulsion, the crystal phenomenon was confirmed by using a transmission electron microscope (TEM).
그 결과 공용 혼합물을 사용한 경우에는 활성성분의 석출 현상없이 200nm내외의 나노에멀젼이 제조된 반면(a), 나머지의 경우에는 모두 결정이 석출되어 피부에 흡수되기 어려운 형태로 확인되었다(b,c)
As a result, when the common mixture was used, nanoemulsions of about 200 nm were prepared without precipitation of the active ingredient (a), whereas in the rest of the cases, crystals precipitated and were hardly absorbed by the skin (b, c).
[실시예 4] Example 4
실시예3에서 제조된 나노 에멀젼의 피부 흡수율을 평가하기 위해 Frantz cell test를 실시하였다. [도4]에서 보는 바와 같이 실시예3의 공융 혼합물을 사용한 경우, 가장 높은 피부흡수율을 확인하였고(b), 실시예 3의 멜라솔브 단독으로 사용한 나노에멀젼의 경우와(c), chemical enhancer인 propylene glycol/EtOH = 3/7 혼합액을 사용한 경우(a)와 비교해도 높은 피부 전달률을 보임을 확인하였다.
Frantz cell test was conducted to evaluate the skin absorption rate of the nanoemulsion prepared in Example 3. As shown in FIG. 4, when the eutectic mixture of Example 3 was used, the highest skin absorption rate was confirmed (b), and in the case of the nanoemulsion used alone with the melasolve of Example 3 (c), which is a chemical enhancer. When propylene glycol / EtOH = 3/7 mixture was used (a), it showed high skin delivery rate.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (8)
상기 페닐링을 가지는 2 종의 화합물들은 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one))을 1.5-3.5:1의 중량비로 포함하는, 화장료 조성물.Two kinds of compounds having a phenyl ring and a polar oil,
The two compounds having the phenyl ring are 5-methyl-2- (methylethyl) phenyl (2E) -3- (3, 4, 5-trimethoxyphenyl) prop-2-enoate (5- methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d ] 1,3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) 1.5-3.5: Cosmetic composition containing by weight ratio of 1.
상기 페닐링을 가지는 2 종의 화합물들은 극성 오일에 용해된 것인, 화장료 조성물. The method of claim 1,
Two kinds of compounds having the phenyl ring is a cosmetic composition that is dissolved in polar oil.
상기 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 화합물 간 중량비는 2:1인, 화장료 조성물. The method of claim 1,
5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl ( 2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolane-5 -Yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d) ], 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) The weight ratio between the compounds is 2: 1, cosmetic composition.
상기 화장료 조성물은 에멀젼인, 화장료 조성물The method according to any one of claims 1 to 3,
The cosmetic composition is an emulsion, cosmetic composition
상기 페닐링을 가지는 2 종의 화합물들은 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one))을 1.5-3.5:1의 중량비로 포함하는, 화장료 조성물의 피부 흡수율을 증진시키는 방법. Mixing two kinds of compounds having a phenyl ring and a polar oil,
The two compounds having the phenyl ring are 5-methyl-2- (methylethyl) phenyl (2E) -3- (3, 4, 5-trimethoxyphenyl) prop-2-enoate (5- methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d ] 1,3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) 1.5-3.5: A method for enhancing the skin absorption rate of the cosmetic composition, comprising a weight ratio of 1.
상기 페닐링을 가지는 2 종의 화합물들은 극성 오일에 용해된 것인, 화장료 조성물의 피부 흡수율을 증진시키는 방법. The method of claim 5,
2 kinds of compounds having the phenyl ring are dissolved in polar oil, the method of enhancing the skin absorption rate of the cosmetic composition.
상기 5-메틸-2-(메틸에틸)페닐 (2E)-3-(3, 4, 5- 트리메톡시페닐)프로프-2-에노에티트 (5-methyl-2-(methylethyl)phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate) 및 2-((3E)-4(2H, 3H-벤조[3, 4-d]1, 3-디옥솔란-5-일)-2-옥소-부트-3-에닐옥시)-5-히드록시-4H-피란-4-원) (2-((3E)-4(2H, 3H-benzo[3, 4-d]1, 3-dioxolan-5-yl)-2-oxo-but-3-enyloxy)-5-hydroxy-4H-pyran-4-one)) 화합물 간 중량비는 2:1인, 화장료 조성물의 피부 흡수율을 증진시키는 방법. The method of claim 5,
5-methyl-2- (methylethyl) phenyl (2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate (5-methyl-2- (methylethyl) phenyl ( 2E) -3- (3,4,5-trimethoxyphenyl) prop-2-enoate) and 2-((3E) -4 (2H, 3H-benzo [3, 4-d] 1, 3-dioxolane-5 -Yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one) (2-((3E) -4 (2H, 3H-benzo [3, 4-d) ] 1, 3-dioxolan-5-yl) -2-oxo-but-3-enyloxy) -5-hydroxy-4H-pyran-4-one)) skin absorption of the cosmetic composition, the weight ratio between the compounds is 2: 1 How to promote.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130148024A KR102066108B1 (en) | 2013-11-29 | 2013-11-29 | Cosmetic compositions containing two kinds of compounds comprising phenyl rings |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130148024A KR102066108B1 (en) | 2013-11-29 | 2013-11-29 | Cosmetic compositions containing two kinds of compounds comprising phenyl rings |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150062895A KR20150062895A (en) | 2015-06-08 |
KR102066108B1 true KR102066108B1 (en) | 2020-01-15 |
Family
ID=53500811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130148024A KR102066108B1 (en) | 2013-11-29 | 2013-11-29 | Cosmetic compositions containing two kinds of compounds comprising phenyl rings |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102066108B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017003092A1 (en) * | 2015-06-30 | 2017-01-05 | (주)아모레퍼시픽 | Cosmetic composition having high dosage form stability |
KR102552729B1 (en) | 2015-06-30 | 2023-07-06 | (주)아모레퍼시픽 | Cosmetic composition having high formulation stability |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531847A (en) * | 2000-05-04 | 2003-10-28 | イー−エル マネージメント コーポレーション | Eutectic mixtures in cosmetic compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100457949B1 (en) * | 2001-09-24 | 2004-11-18 | 주식회사 태평양 | Ester compound of 3,4,5-trimethoxy phenylacetic acid, 3,4,5-trimethoxy cinnamic acid or 3,4,5-trimethoxy hydrocinnamic acid and preparation method thereof, and whitening cosmetic composition containing said compound |
KR101141929B1 (en) | 2009-10-01 | 2012-05-09 | 제주특별자치도 | Skin Whitening Composition |
KR101626473B1 (en) * | 2009-11-30 | 2016-06-02 | (주)아모레퍼시픽 | Composition for external application to the skin containing cyclohexane dicarboxylic acid derivatives |
KR101853718B1 (en) * | 2011-09-02 | 2018-05-03 | (주)아모레퍼시픽 | Method for preparing derivatives of kojic acid |
-
2013
- 2013-11-29 KR KR1020130148024A patent/KR102066108B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531847A (en) * | 2000-05-04 | 2003-10-28 | イー−エル マネージメント コーポレーション | Eutectic mixtures in cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
KR20150062895A (en) | 2015-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69823663T2 (en) | Self-emulsifiable Formulation Containing Lipophilic Compounds | |
JP2835985B2 (en) | External cream preparation for skin | |
KR20110067115A (en) | Modified release emulsions for application to skin or vaginal mucosa | |
Nanda Kishore et al. | Solid self microemulsification of Atorvastatin using hydrophilic carriers: a design | |
US20090227552A1 (en) | Fulvestrant formulations | |
EP2948134B1 (en) | Compositions for transdermal delivery of mtor inhibitors | |
JP2017503866A (en) | Composition for self-emulsifying drug delivery system comprising dutasteride | |
CN103889426A (en) | Solution for oral administration | |
KR102066108B1 (en) | Cosmetic compositions containing two kinds of compounds comprising phenyl rings | |
JP6386738B2 (en) | Oil-in-water (O / W) type emulsion composition, method for producing oil-in-water (O / W) type emulsion composition, and skin external preparation | |
GB1567890A (en) | Instillation composition | |
WO2015107544A4 (en) | Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them | |
KR101819249B1 (en) | Ketoprofen-containing aqueous adhesive skin patch | |
Hou et al. | Enhanced permeation of diazepam through artificial membranes from supersaturated solutions | |
DE202016008851U1 (en) | Ready-to-use bortezomib solution | |
US20160143848A1 (en) | Neat liquid pharmaceutical formulations | |
TWI481416B (en) | Water-based emulsified composition | |
CN110139641B (en) | External composition | |
Wiranidchapong et al. | Thermal, mechanical and drug release characteristics of an acrylic film using active pharmaceutical ingredient as non-traditional plasticizer | |
CN116270453B (en) | Bilobalide solution and preparation process thereof | |
WO2019240212A1 (en) | Formulation containing pharmaceutically active ingredient | |
JP2008013493A (en) | Method for storing glycerol solution containing ascorbic acid in high concentration | |
KR20150000371A (en) | Solubilizing composition of insoluble cosmetic compounds and the method for preparing the same | |
ZA201102353B (en) | A parasiticidal composition | |
KR20190124535A (en) | Aqueous composition containing idebenone and cosmetic composition using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |